Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 14 08 2020
revised: 19 10 2020
accepted: 22 10 2020
pubmed: 1 11 2020
medline: 30 7 2021
entrez: 31 10 2020
Statut: ppublish

Résumé

Definitive radiation therapy (RT), with or without concurrent chemotherapy, is an alternative to radical cystectomy for patients with localized, muscle-invasive bladder cancer (MIBC) who are either not surgical candidates or prefer organ preservation. We aim to synthesize an evidence-based guideline regarding the appropriate use of RT. We performed a Preferred Reporting Items for Systematic Reviews and Meta-analyses literature review using the PubMed and Embase databases. Based on the literature review, critical management topics were identified and reformulated into consensus questions. An expert panel was assembled to address key areas of both consensus and controversy using the modified Delphi framework. A total of 761 articles were screened, of which 61 were published between 1975 and 2019 and included for full review. There were 7 well-designed studies, 20 good quality studies, 28 quality studies with design limitations, and 6 references not suited as primary evidence. Adjuvant radiation therapy after cystectomy was not included owing to lack of high-quality data or clinical use. An expert panel consisting of 14 radiation oncologists, 1 medical oncologist, and 1 urologist was assembled. We identified 4 clinical variants of MIBC: surgically fit patients who wish to pursue organ preservation, patients surgically unfit for cystectomy, patients medically unfit for cisplatin-based chemotherapy, and borderline cystectomy candidates based on age with unilateral hydronephrosis and normal renal function. We identified key areas of controversy, including use of definitive radiation therapy for patients with negative prognostic factors, appropriate radiation therapy dose, fractionation, fields and technique when used, and chemotherapy sequencing and choice of agent. There is limited level-one evidence to guide appropriate treatment of MIBC. Studies vary significantly with regards to patient selection, chemotherapy use, and radiation therapy technique. A consensus guideline on the appropriateness of RT for MIBC may aid practicing oncologists in bridging the gap between data and clinical practice.

Identifiants

pubmed: 33127490
pii: S0360-3016(20)34448-5
doi: 10.1016/j.ijrobp.2020.10.031
pii:
doi:

Substances chimiques

Radium W90AYD6R3Q

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

953-963

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Tru-Khang T Dinh (TT)

Department of Radiation Oncology, University of Washington, Seattle, Washington.

Timur Mitin (T)

Department of Radiation Medicine, Oregon Health Sciences University, Portland, Oregon. Electronic address: mitin@ohsu.edu.

Hilary P Bagshaw (HP)

Department of Radiation Oncology, Stanford University Clinics, Palo Alto, California.

Karen E Hoffman (KE)

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.

Clara Hwang (C)

Department of Hematology/Oncology, Henry Ford Health System, Detroit, Michigan.

R Jeffrey Karnes (R)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Amar U Kishan (AU)

Department of Radiation Oncology, University of California at Los Angeles Medical Center, Los Angeles, California.

Stanley L Liauw (SL)

Department of Radiation Oncology, University of Chicago, Chicago, Illinois.

Shane Lloyd (S)

Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, Utah.

Louis Potters (L)

Department of Radiation Oncology, Northwell Health, New Hyde Park, New York.

Timothy N Showalter (TN)

Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.

Al V Taira (AV)

Sutter Health Radiation Oncology, San Mateo, California.

Neha Vapiwala (N)

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.

Nicholas G Zaorsky (NG)

Department of Radiation Oncology, Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania.

Anthony V D'Amico (AV)

Department of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer, Institute, Boston, Massachusetts.

Paul L Nguyen (PL)

Department of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer, Institute, Boston, Massachusetts.

Brian J Davis (BJ)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH